^
    4d
    A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) (clinicaltrials.gov)
    P3, N=172, Active, not recruiting, Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Trial completion date: Nov 2025 --> Feb 2025 | Trial primary completion date: Sep 2025 --> Jul 2024
    Trial completion date • Trial primary completion date
    |
    Winrevair (sotatercept-csrk)
    5d
    A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia (clinicaltrials.gov)
    P2, N=249, Recruiting, Bristol-Myers Squibb | Trial primary completion date: Nov 2025 --> Jul 2027 | Trial completion date: Jun 2026 --> Aug 2034
    Trial completion date • Trial primary completion date
    |
    Reblozyl (luspatercept-aamt)
    7d
    Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia (clinicaltrials.gov)
    P2, N=99, Recruiting, Celgene | Trial completion date: Nov 2026 --> Jun 2035 | Trial primary completion date: Jun 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    Reblozyl (luspatercept-aamt)
    9d
    20-C-0012: Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies (clinicaltrials.gov)
    P1, N=100, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2027
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    bintrafusp alfa (M7824) • PDS01ADC
    11d
    Study of ZGGS18 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=222, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial primary completion date: Nov 2024 --> Nov 2025
    Trial primary completion date • Metastases
    |
    ZGGS18
    12d
    An Engineered Sirpα Fused to Anti-Pd-L1 and Tgf-β Fusion Protein (HCB301) in Subjects with Selected Advanced Tumors (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, FBD Biologics Limited | Initiation date: Sep 2024 --> Jan 2025
    Trial initiation date • Metastases
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    14d
    Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms (clinicaltrials.gov)
    P2, N=70, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Sep 2024 --> Jun 2025
    Trial primary completion date
    |
    SF3B1 (Splicing Factor 3b Subunit 1)
    |
    SF3B1 mutation
    |
    Reblozyl (luspatercept-aamt)
    15d
    Iron overload in acquired sideroblastic anemias and MDS: pathophysiology and role of chelation and luspatercept. (PubMed, Hematology Am Soc Hematol Educ Program)
    Luspatercept, which can reduce SMAD2/SMAD3-dependent signaling implicated in suppression of erythropoiesis, may obviate the need for red blood cell transfusion in MDS-RS for more than a year, thereby diminishing further iron loading. However, luspatercept cannot be expected to substantially reduce the existing iron overload.
    Review • Journal
    |
    SF3B1 (Splicing Factor 3b Subunit 1) • ERFE (Erythroferrone) • SMAD3 (SMAD Family Member 3)
    |
    SF3B1 mutation
    |
    Reblozyl (luspatercept-aamt)
    17d
    Discovery and preclinical evaluation of BPB-101: a novel triple functional bispecific antibody targeting GARP-TGF-β complex/SLC, free TGF-β and PD-L1. (PubMed, Front Immunol)
    Furthermore, BPB-101 showed a favorable safety profile in nonhuman primate (NHP) toxicity studies. BPB-101 is a potentially promising therapeutic candidate that may address unmet clinical needs in cancer immunotherapy, thus, BPB-101 warrants further clinical investigation.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    BPB-101
    17d
    PIONEER: Pirfenidone to Prevent Fibrosis in Ards. (clinicaltrials.gov)
    P3, N=130, Recruiting, Università Vita-Salute San Raffaele | Trial primary completion date: Oct 2024 --> Jun 2025
    Trial primary completion date
    18d
    Preclinical studies on the antitumor and non-toxic effect of combining pirfenidone with vinorelbine and carboplatin in non-small cell lung cancer. (PubMed, Int J Cancer)
    Most interestingly, the triplet treatment exhibited a safer toxicological profile than the doublet (vinorelbine plus carboplatin) currently applied in the clinical practice. Altogether, these preclinical data support the possibility of repurposing pirfenidone in combination with vinorelbine or with vinorelbine plus carboplatin for NSCLC perioperative treatment, improving therapeutic efficacy while reducing toxicity.
    Preclinical • Journal
    |
    VIM (Vimentin)
    |
    VIM expression
    |
    carboplatin • vinorelbine tartrate
    19d
    Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, PureTech
    New P1 trial
    |
    nintedanib
    20d
    Pirfenidone promotes cell cycle arrest and apoptosis of triple‑negative breast cancer cells by suppressing Hedgehog/GLI1 signaling. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    Interestingly, GLI1 overexpression attenuated the influences of pirfenidone on the proliferation, cell cycle and apoptosis of TNBC cells. Collectively, pirfenidone arrests the cell cycle and promotes apoptosis of TNBC cells by suppressing Hedgehog/GLI1 signaling.
    Journal • PARP Biomarker • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • PTCH1 (Patched 1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • GLI1 (GLI Family Zinc Finger 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
    |
    BCL2 expression • BAX expression
    24d
    Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms (clinicaltrials.gov)
    P2, N=70, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: May 2025 --> Sep 2025 | Trial primary completion date: May 2025 --> Sep 2024
    Trial completion date • Trial primary completion date
    |
    SF3B1 (Splicing Factor 3b Subunit 1)
    |
    SF3B1 mutation
    |
    Reblozyl (luspatercept-aamt)
    24d
    Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI) (clinicaltrials.gov)
    P1, N=16, Terminated, Sanofi | N=24 --> 16 | Trial completion date: Jun 2025 --> Nov 2024 | Recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Nov 2024; Sponsor decision to prematurely stop the study, not linked to any safety concern.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    COL1A1 (Collagen Type I Alpha 1 Chain)
    |
    SAR439459
    26d
    NCI-2018-00919: M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability (clinicaltrials.gov)
    P1/2, N=4, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | N=74 --> 4
    Trial completion • Enrollment change • Combination therapy • Circulating tumor DNA • Metastases
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    bintrafusp alfa (M7824)
    1m
    A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC (clinicaltrials.gov)
    P2, N=87, Not yet recruiting, LISCure Biosciences
    New P2 trial
    1m
    SOTERIA: A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12) (clinicaltrials.gov)
    P3, N=700, Recruiting, Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Trial completion date: Nov 2027 --> Feb 2031 | Trial primary completion date: Sep 2027 --> Feb 2031
    Trial completion date • Trial primary completion date
    |
    Winrevair (sotatercept-csrk)
    1m
    Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) (clinicaltrials.gov)
    P1/2, N=53, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency)
    |
    TMB-H • MSI-H/dMMR
    |
    bintrafusp alfa (M7824) • epacadostat (INCB024360) • Anktiva (nogapendekin alfa inbakicept-pmln)
    1m
    Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis (clinicaltrials.gov)
    P1, N=9, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed | N=24 --> 9
    Trial completion • Enrollment change
    |
    BMS-986416
    1m
    LIGHTRAY: A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024) (clinicaltrials.gov)
    P2, N=160, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Winrevair (sotatercept-csrk)
    1m
    A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies (clinicaltrials.gov)
    P1, N=19, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    BMS-986416
    1m
    Sox-PH: 129 Xenon Imaging in Patients Treated with Sotatercept (clinicaltrials.gov)
    P2, N=14, Not yet recruiting, Bastiaan Driehuys | Initiation date: Sep 2024 --> Dec 2024
    Trial initiation date
    |
    Winrevair (sotatercept-csrk)
    1m
    Phoenix: Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD (clinicaltrials.gov)
    P2, N=22, Recruiting, Associazione Qol-one | Trial completion date: Nov 2028 --> Dec 2029 | Trial primary completion date: Apr 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    Reblozyl (luspatercept-aamt)
    1m
    Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON). (clinicaltrials.gov)
    P2, N=11, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Aug 2025 --> Jul 2024 | Trial primary completion date: Aug 2025 --> Jul 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    bintrafusp alfa (M7824)
    1m
    Phase II clinical study on the efficacy, safety, and pharmacokinetics of HS-20106 in IPSS-R extremely low-risk, low-risk, or moderate risk myelodysplastic syndrome (MDS) anemia subjects (ChiCTR2400090140)
    P2, N=176, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College.; Institute of Hematolog
    New P2 trial
    |
    elritercept (KER-050)
    2ms
    Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Groupe Francophone des Myelodysplasies
    New P1 trial
    |
    arsenic trioxide • Reblozyl (luspatercept-aamt)
    2ms
    CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages. (PubMed, NPJ Precis Oncol)
    The TGFβ receptor inhibitor galunisertib showed promising efficacy in patients with pancreatic ductal adenocarcinoma (PDAC) in the phase 2 H9H-MC-JBAJ study. TGFβ inhibition redirects macrophage polarization to M1, reducing Lif and shifting PDAC cells to a more epithelial/classical phenotype, improving gemcitabine sensitivity. This study supports exploring TGFβ-targeting agents in PDAC with a mesenchymal/basal-like ecotype driven by high CCL3 levels.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1) • CCL3 (C-C Motif Chemokine Ligand 3)
    |
    gemcitabine • galunisertib (LY2157299)
    2ms
    LIGHTRAY: A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024) (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, Merck Sharp & Dohme LLC
    New P2 trial
    |
    Winrevair (sotatercept-csrk)
    2ms
    Right Ventricular Compensation with Sotatercept: a Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE) (clinicaltrials.gov)
    P4, N=20, Not yet recruiting, Amsterdam UMC, location VUmc
    New P4 trial
    |
    Winrevair (sotatercept-csrk)
    2ms
    REPEAT: Real-life-persistence to Antifibrotic Treatments (clinicaltrials.gov)
    P=N/A, N=800, Active, not recruiting, Boehringer Ingelheim | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    nintedanib
    2ms
    NCI-2018-01184: M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer (clinicaltrials.gov)
    P1, N=20, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    bintrafusp alfa (M7824)
    2ms
    Comparison of the Efficacy of Pirfenidone and Nintedanipine in Pulmonary Fibrosis (clinicaltrials.gov)
    P=N/A, N=152, Completed, Karadeniz Technical University
    New trial
    |
    nintedanib
    2ms
    Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa. (PubMed, Front Oncol)
    Epoetin alfa was used simultaneously in 31 patients (60.7%). The effect was particularly high in the IPSS-M low and very low groups. We believe that the relatively high response rate in our patients was influenced by the frequent use of a higher dose (1.75 mg/kg) and especially by adding ESA to luspatercept in poorly responding patients.
    Journal • Real-world evidence • Real-world
    |
    SF3B1 (Splicing Factor 3b Subunit 1) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    SF3B1 mutation
    |
    Reblozyl (luspatercept-aamt)
    2ms
    Pirfenidone mitigates demyelination and electrophysiological alterations in multiple sclerosis: Targeting NF-κB, sirt1, and neurotrophic genes. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    These effects could be mediated by modulating the NF-κB, SIRT1, NGF, and neuregulin-1 pathways. Pir is a promising agent for treating MS.
    Journal
    |
    NRG1 (Neuregulin 1) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1) • IL17A (Interleukin 17A) • SIRT1 (Sirtuin 1) • PIR (Pirin)
    2ms
    AIHA ITP CIN: Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Trial completion date: Jun 2030 --> Jun 2035 | Trial primary completion date: Sep 2026 --> Sep 2030
    Trial completion date • Trial primary completion date
    |
    Reblozyl (luspatercept-aamt)
    2ms
    Anti-Inflammatory Oxysterol, Oxy210, Inhibits Atherosclerosis in Hyperlipidemic Mice and Inflammatory Responses of Vascular Cells. (PubMed, Cells)
    These findings suggest that Oxy210 could be a drug candidate for targeting both NASH and atherosclerosis, as well as chronic inflammation associated with the manifestations of metabolic syndrome.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CCL2 (Chemokine (C-C motif) ligand 2) • APOE (Apolipoprotein E) • IL1B (Interleukin 1, beta) • VCAM1 (Vascular Cell Adhesion Molecule 1)
    |
    Oxy210
    2ms
    Pirfenidone Antagonizes TGF-β1-Mediated Gabapentin Resistance via Reversal of Desmoplasia and the 'Cold' Microenvironment in Pancreatic Cancer. (PubMed, Cancer Lett)
    Hmox1highiCAFs overexpressed the Cxcl10 receptor (Sdc4) and facilitated functional CD8+ T-cell infiltration through the Tnfsf9-Tnfrsf9 axis. Overall, our nanodrugs reshape the phenotype of CAFs and enhance functional CD8+ T-cell infiltration into tumors, holding the potential to be a safe and promising therapy for PDAC.
    Journal
    |
    CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • TNFRSF9 (TNF Receptor Superfamily Member 9) • HMOX1 (Heme Oxygenase 1) • SDC4 (Syndecan 4) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    CXCL10 overexpression • HMOX1 expression • CXCL10 expression • HMOX1 overexpression
    2ms
    CA056-1083: A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, Bristol-Myers Squibb | Not yet recruiting --> Withdrawn | N=86 --> 0
    Enrollment change • Trial withdrawal • HEOR • Real-world evidence • Real-world
    |
    Reblozyl (luspatercept-aamt)
    2ms
    Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC (clinicaltrials.gov)
    P1, N=48, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Sep 2024 --> Jan 2025
    Trial completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • EGFR mutation + ALK mutation
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed
    3ms
    Targeted therapies for myelodysplastic Syndromes/Neoplasms (MDS): current landscape and future directions. (PubMed, Expert Rev Anticancer Ther)
    Despite some promising results, many therapies remain in early development or have faced setbacks, emphasizing the need for a more comprehensive understanding of the disease's pathobiology. Continued research into targeted therapies, homogenous clinical trial designs, as well as increased incorporation of molecular prognostic tools and artificial intelligence into trial design are essential for developing effective treatments for MDS and improving patient outcomes.
    Review • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    Venclexta (venetoclax) • azacitidine • Reblozyl (luspatercept-aamt) • Rytelo (imetelstat)
    3ms
    A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study). (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Keros Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed